Ulipristal acetate 5mg prescribing for uterine fibroids by all CCGs

Why it matters: The MHRA has a clear safety direction advising that patients taking Esmya (ulipristal acetate) for uterine fibroids should STOP their treatment IMMEDIATELY.

Any prescribing on this measure should prompt investigation to identify patients and ensure the treatment is stopped and followup blood tests arranged.

Please note that this is an experimental measure to support a new type of alert. We would be grateful for any feedback at [email protected].

Description: Number of items for ulipristal acetate 5mg per 1000 patients


Tagged as: Safety, Reproductive system (or browse all measures)

CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? We can often provide one-off custom extracts from our prescribing data for free. to find out more.